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Abstract
Background: Patients with type 2 diabetes (T2DM) often have poor glycemic control on first-line pharmacologic
therapy and require treatment intensification. Intensification decisions can be difficult because of many available
options and their many benefits and risks. The American Diabetes Association recommends patient-centered,
evidence-based tools supporting shared decision-making between patients and clinicians. We developed a patient
decision aid (PDA) targeting decisions about treatment intensification for T2DM. Our objective was to determine the
effectiveness of this PDA for patients with T2DM on metformin who require treatment intensification.
Methods: This study was a pragmatic randomized controlled trial conducted in 27 US primary care and endocrinology
clinics. Subjects were English-speaking adults with T2DM receiving metformin with persistent hyperglycemia who were
recommended to consider medication intensification. Subjects were randomized to receive either the PDA or usual care
(UC). Main outcome measures were change in knowledge, decisional self-efficacy, and decisional conflict.
Results: Of 225 subjects enrolled, 114 were randomized to the PDA and 111 to UC. Mean [SD] age was 52 [1] years, time
since T2DM diagnosis was 6 [+/−6] years, 45.3 % were male, and most (55.5 %) were non-Caucasian. Compared to UC,
PDA users had significantly larger knowledge gains (35.0 % [22.3] vs 9.9 % [22.2]; P < 0.0001) and larger improvements in
self-efficacy (3.7 [16.7] vs−3.9 [19.2]; P < 0.0001) and decisional conflict (−22.2 [20.6] vs−7.5 [16.6]; P < 0.0001).
Conclusions: The PDA resulted in substantial and significant improvements in knowledge, decisional conflict and
decisional self-efficacy. Decisional conflict scores after PDA use were within the range that correlates with effective
decision-making. This PDA has the potential to facilitate shared-decision-making for patients with T2DM.
Trial registration: NCT02110979
Keywords: Type 2 diabetes mellitus, Antihyperglycemic medication, Shared decision-making, Patient decision aid,
Decisional conflict, Decision self-efficacy
Background
Patients with type 2 diabetes mellitus (T2DM) with per-
sistent hyperglycemia are at high risk of developing
disease-related complications [2, 3]. Choosing therapy
for patients when first-line therapy with metformin is no
longer effective is complex and involves difficult trade-
offs. Therapeutic options include adding an additional
oral or injectable agent, including insulin [4]. A variety
of antihyperglycemic medications are now available, each
differing in important dimensions (e.g., effectiveness,
side-effects, hypoglycemia risk, cost, impact on weight,
and contraindications). There is no single best treatment
appropriate for all patients, but rather the best treatment
depends on what is important to each patient, their
treatment goals, their underlying disease, and their co-
morbidities. Patients with diabetes often have inadequate
information about their disease, their treatment options,
and the consequences of their treatment decision, which
can interfere with informed decision-making [5, 6]. Inad-
equate knowledge about medication and self-care in pa-
tients with diabetes negatively impacts self-efficacy, the
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belief that one is informed, supported, capable of taking
steps and making decisions to improve health [7, 8]. Low
self-efficacy is associated with lack of follow through on
healthy intentions and decisions [9]. Inadequate knowledge
and support also increase the likelihood of decisional con-
flict which is manifested by delays in decision-making,
vacillating between choices, questioning values and ten-
sion [10]. Improving knowledge can promote diabetes
self-efficacy, reduce decisional conflict, improve self-
management behaviors [1, 11, 12], improve medication
adherence [13, 14] and glycemic control [15–17], which
should lead to improved clinical outcomes.
The American Diabetes Association (ADA) [18], and
other medical organizations [19–22] recommend a patient-
centered approach and patient engagement, including
shared-decision making, to choosing among antihypergly-
cemic medications. They encourage clinicians to ensure
that patients understand the decision and consider the
risks and benefits involved in intensifying treatment (in-
cluding the risk of hypoglycemia) [23, 24] and consider pa-
tient preferences. Helping patients make decisions aligned
with their personal values is is integral to patient-centered
care, an Institute of Medicine (IOM) mandate [25]. Yet
implementing shared decision-making recommendations
as a component of routine clinical care has been limited
because of practice and health system barriers (e.g., limited
time) and patient barriers (e.g., health literacy) [26]. Adop-
tion of these recommendations will likely require targeted
decision support tools to overcome these barriers.
Patient decision aids (PDAs) are educational tools de-
signed to help patients make treatment decisions in col-
laboration with their clinician and promote shared
decision-making. The Cochrane Collaboration system-
atic review of PDAs found they consistently improved
knowledge, helped subjects match their values to their
choices, and reduced passivity in decision-making [27].
PDAs focusing on patients with T2DM addressed statin
choice [28–31] goal-setting [32, 33] metabolic control
[34], addition of insulin [35], and starting or changing
statins or antihyperglycemic treatment [36]. These PDAs
promoted patients’ discussions of medications with their
clinician, realistic expectations, autonomy, trust, engage-
ment in decision-making, patient knowledge, risk per-
ceptions, and documented goals, but none addressed
decisional self-efficacy. Self-efficacy has been shown to
be an important mediator of health decisions and health
behaviors [37]. Additionally, none of these PDAs targeted
the important decision about further treatment options
that confronts the many patients with T2DM for whom
first-line therapy with metformin is no longer effective
and who need to consider further treatment options. This
study was conducted in 27 non-academic sites across the
country, giving much-needed evidence about the use of
PDAs is real world environments.
The objective of this study was to determine the impact
of a PDA for decisions about antihyperglycemic medica-
tions on key elements of shared decision-making (know-
ledge, self-efficacy, and decisional conflict) in a pragmatic
randomized controlled trial involving a diverse national
sample of subjects with T2DM during the course of rou-
tine clinical care.
Methods
We conducted a multicenter randomized controlled prag-
matic trial (Clinical Trials.gov Identifier: NCT02110979).
Setting and participants
This trial was conducted in 27 primary care or endocrin-
ology clinics throughout the US (Additional file 1). To im-
prove the generalizability of the study, we restricted our
national U.S. sample to non-academic clinical sites. Clinics
were identified through a nationwide email list of providers
maintained by the Primary Care Network™ (Springfield,
MO), supplemented by providers’ emails obtained through
a medical marketing database (IMD®). Clinicians were in-
vited to participate and were selected if they were primary
care clinicians or endocrinologists treating a minimum of
ten patients with T2DM each week, had access to elec-
tronic medical records and/or electronic laboratory data,
had a nurse, diabetes educator or other clinical staff sup-
port to facilitate subject identification, and were not affili-
ated with an academic institution. Approximately 2000
emailed invitations were sent; 68 sites responded; 32 were
selected and 27 enrolled at least one subject.
Subject inclusion criteria: Eligible subjects were English-
speaking adults with T2DM who were advised by their
clinician to consider additional antihyperglycemic medica-
tion to a metformin-containing regimen to improve gly-
cemic control. Subjects were further required to have a
valid email address, access to the internet via a personal
computer, and the ability to complete surveys online.
Subject exclusion criteria: Excluded were pregnant
women, clinical trial participants, subjects already tak-
ing two or more medications in addition to metformin,
or those with a lifetime exposure to more than three
antihyperglycemic agents.
Patient Consent Procedures: All study procedures were
approved by the New England IRB. Patient recruitment
was intended to simulate how the PDA would be used in
the ‘real world’ after trial completion. Potential study sub-
jects were identified using medical records based on re-
cent laboratory testing assessing glycemic control and
rosters of appointments. Potential subjects were referred
to the principle investigator by their clinician. Subjects
were emailed a link to the study website (maintained by
Qualtrics®) which screened for eligibility, obtained online
consent, and collected baseline data. Subjects were ran-
domized to either the online intervention (PDA group) or
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usual care (UC group). UC subjects were directed to
follow-up with their doctor at an upcoming appointment
as they normally would. Usual care was selected as the
control arm in order to understand the incremental benefit
of the PDA beyond care typically received during a clinical
consultation and to make findings relevant to clinicians
considering incorporating PDAs into routine practice. Re-
ferring clinicians were blinded to group assignment, unless
they were incidentally un-blinded by subjects during a
clinical consultation subsequent to enrollment (e.g.,
subjects mentioning the PDA or its contents during an
office visit). Consistent with an intention-to-treat (ITT)
principle [38, 39], we attempted to minimize loss to follow-
up by monitoring subjects and prompting non-responders
or partial responders to complete the intervention and/or
assessments through phone and email reminders.
The PDA
The interactive Diabetes Decision Aid for T2DM targeted
decisions about antihyperglycemic medication intensifica-
tion for subjects for whom first-line treatment with metfor-
min is no longer effective. The evidence-based PDA was
designed to help subjects understand T2DM, its natural
history, and the full range of treatment options, including
sulfonylureas, dipeptidyl peptidase-4 (DPP-4 s) inhibitors,
thiazolidinediones (TZDs), sodium-glucose co-transporter
two (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1 s)
agonists, and insulin. To make the information more sali-
ent to subjects, evidence about the risks and benefits of dif-
ferent treatment options were organized and presented
according to key preference domains that were identified
during the development process [40] and through two
focus groups with affected subjects. These domains in-
clude: 1) expected degree of glycemic control, 2) impact on
weight, 3) risk of hypoglycemia and other adverse events,
4) route of administration, 5) frequency of dosing and
route of administration and blood glucose monitoring, and
6) cost of therapy. The PDA described and compared the
potential benefits and risks of the treatments in each of
these domains and helped subjects explore their prefer-
ences and values through values clarification exercises [41].
It included questions eliciting their long-term goals for
therapy and their concerns about antihyperglycemic medi-
cations. A summary “fact sheet” compared the risks and
benefits of each class of medication using voice-over de-
scriptions and simple graphics. Potential risks and benefits
were illustrated using color-coded pictographs with plain
language summaries, presented in a balanced, unbiased
manner (Fig. 1).
The PDA did not allow subjects to skip through content
in order to ensure that all key content areas were reviewed.
It did not discuss lifestyle interventions (e.g., smoking, diet
and exercise) but it did enable subjects to request informa-
tion on these topics. The PDA was developed in accordance
with the International Patient Decision Aid Standards cri-
teria [42] in collaboration with a multidisciplinary team
with expertise in clinical medicine, shared decision-making,
and patient education [38].
Intervention protocol
Prior to enrolling any subjects, clinicians and staff were
encouraged to review the online PDA. Clinicians and
clinic staff involved in identifying potential subjects par-
ticipated in brief training sessions (30–60 min) on the
use of the PDA and study procedures. Subjects random-
ized to the PDA group received computer-generated
emails asking them to view information “recommended
by their doctor” and a link to the PDA. Reminder mes-
sages were sent daily until the subject viewed the PDA
in its entirety. Subjects who had not viewed the PDA
within 5 days were contacted by phone or e-mail as a
further reminder. The PDA took approximately 30 min
to complete and subjects were encouraged to watch it as
many times as they wanted and to make use of an online
note-taking system to record questions or comments
that could be shared with their doctor. Subjects were en-
couraged to view the PDA with others involved in the
decision-making process.
Outcomes and data collected
Study data were collected at baseline and 4–6 weeks fol-
lowing enrollment into the study for both study groups.
In the PDA group, a brief survey was distributed shortly
after viewing the PDA (within approximately 24 h) to as-
sess opinions related to detail and length of content. A
four to 6 weeks measurement time frame was selected in
order to capture the impact of the PDA on knowledge
gained, self- efficacy, and decisional conflict, outcomes
which are best captured within the first month after ex-
posure to the PDA.
Clinicians responded to similar questions. Subjects were
paid $25 at each data collection point.
Baseline data
All subject data was self-reported and included socio-
demographics (age, gender, race/ethnicity, educational
level, employment and insurance status), duration of
T2DM, height and weight, and relevant co-existing con-
ditions (Table 1). Subjects were asked about their stage
of decision-making [43], (e.g., had they begun to think
about the decision, had they already made a decision),
their preference for making clinical decisions, (e.g., do
they prefer to have their clinician make decisions, prefer
shared-decision-making or prefer making decisions on
their own) [44] and the relative importance of competing
values related to domains of diabetes medication decision-
making. Subject values assessed included the importance
of: managing blood sugar to a goal; taking a medication
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that might help lose weight or not cause weight gain;
avoiding hypoglycemia (a “low”); avoiding side-effects such
as pancreatitis, fractures, urinary tract infections and yeast
infection; treatment costs, avoiding injections; and dosing
convenience (i.e., taking medication more than once a
day). These were assessed using a scale from 0 to 10, with
0 representing not at all important, and ten representing
extremely important.
Primary outcome
The primary outcome of this study was knowledge
gained about medication, using a scale developed for the
study to assess understanding of how different treat-
ments differ in terms of their 1) impact on glycemic
control (amount and durability), 2) impact on weight, 3)
risk of hypoglycemia and other adverse events, 4) route
of administration, 5) frequency of dose administration
and blood glucose monitoring, and 6) financial costs.
Knowledge was assessed by asking subjects to respond
to 17 statements about antihyperglycemic medications
that were either true or false (Additional file 1). To dis-
courage guessing, we offered a “not sure” response op-
tion. We calculated the percentage of correct answers.
We also asked subjects to rate their confidence in their
responses using a ten point Likert scale (from 1, “I am
certain this is incorrect” to ten, “I am certain this is cor-
rect”, with five corresponding to “not sure”). All ques-
tions were pretested on ten subjects with T2DM and
revised accordingly. The pretest suggested uniform com-
prehension of all but one item, which was subsequently
reworded. A composite “perceived knowledge confi-
dence” score was summed and normalized to a 0–100
scale. Knowledge gained was calculated by subtracting
baseline from follow-up scores.
Fig. 1 Type 2 Diabetes Medications Comparison Chart*. PDA “Fact Sheet”
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Table 1 Baseline characteristics
PDA (n = 114) Usual Care (n = 111) p-valuea
Mean age (Mean, SD) 53.0 (13.8) 51.6 (11.5) 0.4121
Male (n, %) 52 (45.6) 50 (45.1) 0.9317
Race/Ethnicity (n, %)
White/Caucasian 53 (46.5) 48 (43.2) 0.6243
Black/African American 32 (28.1) 31 (27.9) 0.9810
Hispanic 14 (12.3) 15 (13.5) 0.8437
Asian/Pacific Islander 5 (4.4) 9 (8.1) 0.2810
Native American or Alaska Native 1 (0.9) 2 (1.8) 0.6183
Other or Multi-Racial 9 (7.9) 6 (5.4) 0.4542
Education (n, %)
Grade School 2 (1.8) 1 (0.9) 0.5786
Some High School 12 (10.5) 2 (1.8) 0.0068
High School Graduate 29 (25.4) 29 (26.1) 0.9062
Some College 30 (26.3) 44 (39.6) 0.0334
College Graduate 26 (22.8) 24 (21.6) 0.8307
Graduate School 15 (13.2) 11 (9.9) 0.4461
Employment (n, %)
Full time 50 (43.9) 60 (54.1) 0.3379
Part time 11 (9.6) 7 (6.3)
Unemployed 15 (13.2) 11 (9.9)
On Disability 19 (16.7) 11 (9.9)
Student 2 (1.8) 2 (1.8)
Homemaker 6 (5.3) 3 (2.7)
Other 11 (9.6) 17 (15.3)
Insurance status (n, %)
PPO 39 (34.2) 49 (44.1) 0.2585
HMO 26 (22.8) 14 (12.6)
Medicare 19 (16.7) 22 (19.8)
Medicaid 16 (14.0) 10 (9.0)
None 6 (5.3) 6 (5.4)
Other 8 (7.0) 10 (9.0)
Years since T2DM Diagnosis (Mean, SD) 6.8 (6.0) 6.5 (5.4) 0.7192
BMI (Mean, SD) 34.4 (8.0) 35.6 (9.4) 0.3152
Underweight (<18.5) (n,%) 0 0 0.8106
Normal (18.5–24.99) 13 (11.4) 11 (9.9)
Overweight (25–29.99) 22 (19.3) 21 (18.9)
Obese class I (30–34.99) 32 (28.1) 27 (24.3)
Obese class II (35–39.99) 15 (13.1) 21 (18.9)
Obese class III (>40) 32 (28.1) 31 (27.9)
Comorbidities and Health Conditions (n,%)
High Blood Pressure 82 (71.9) 69 (62.2) 0.1190
Heart Disease 10 (8.8) 9 (8.1) 0.8579
Stroke 3 (2.6) 5 (4.5) 0.4951
High Cholesterol 59 (51.8) 57 (51.4) 0.9518
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Secondary outcomes
Secondary outcomes included changes in the Decision
Self Efficacy Scale (DSES) and Decisional Conflict Scale
(DCS). The DSES assesses subjects’ self-confidence or be-
lief in one’s abilities in decision-making. In testing, the
DSES internal reliability coefficient was .92, and the scale
significantly discriminated between subjects who did and
did not make health-related decisions [45]. The DSES is
summed and scored from 0 to 100 with 100 representing
complete self-efficacy and 0 representing complete lack of
self-efficacy. The DCS [46] measures overall uncertainty
in making a health-related decision and includes subscales
that address the factors that contribute to uncertainty
(feeling uncertain, informed, clear about values, supported
in effective decision-making). In validation testing, the
test-retest reliability coefficient of the DCS was 0.81. In-
ternal consistency coefficients ranged from 0.78 to 0.92.
The DCS discriminated significantly between those who
had strong intentions for and ultimately acted upon deci-
sion making and those whose intentions were uncertain
[10]. The DCS and subscales are scored from 0 to 100;
lower scores correspond to less decisional conflict [47].
Changes in DSES and DCS were calculated by subtracting
baseline from follow-up scores.
Data analyses
All subjects were analyzed in the arm to which they
were randomized (ITT). Baseline demographic, past
medical history and responses to baseline decision-
related questionnaires were compared between treat-
ment groups in univariate analyses to assess the success
of randomization, using t-tests for continuous and X2
or Fisher’s exact for categorical data. For the primary
and secondary outcomes, unadjusted mean differences
in knowledge, DSES and DCS scores were calculated by
subtracting post from baseline scores and comparing
those values using t-tests. Covariate adjusted analysis
on primary and secondary outcome were conducted
using generalized linear models (GLM). Dependent var-
iables in the models were knowledge gained, knowledge
confidence score, DCS and DSES. Covariates included
in the models were those of theoretical interest to the
investigators (e.g. stage of decision-making, race/ethni-
city) and those relating to failed randomization, using a
threshold of p <0.1.
Adherence to the intervention group (viewing the
PDA) was included in GLM models as a dichotomous
variable (all or none), based upon tracking each partici-
pant’s unique subject code for accessing the PDA. UC
Table 1 Baseline characteristics (Continued)
High Triglycerides 23 (20.2) 27 (24.3) 0.4542
Gallbladder Disease 8 (7.0) 5 (4.5) 0.4192
Liver Disease 2 (1.8) 2 (1.8) 1.000
Kidney Disease or Renal Failure 1 (0.9) 2 (1.8) 0.6183
Pancreatitis 3 (2.6) 5 (4.5) 0.4951
Insulin Resistance 5 (4.4) 7 (6.3) 0.5216
Osteoporosis 3 (2.6) 2 (1.8) 1.000
Peripheral Vascular Disease 5 (4.4) 5 (4.5) 1.000
Hypoglycemia 3 (2.6) 5 (4.5) 0.4951
Ketoacidosis 0 2 (1.8) 0.2423
Neuropathy 12 (10.5) 9 (8.1) 0.5330
Yeast or Urinary Tract Infection 22 (19.3) 11 (9.9) 0.0466
Baseline Knowledge, Decisional Conflict and Decision Self-efficacy
Knowledge (% correct, mean, SD) 20.4 % (15.7) 22.6 % (16.9) 0.3150
Knowledge confidence score (mean, SD) 56.1 (5.6) 56.9 (8.6) 0.4035
Decisional Conflict Scale (DCS) (mean, SD) 45.8 (18.8) 45.4 (16.9) 0.8559
Uncertainty subscale 49.9 (24.5) 50.8 (24.9) 0.7915
Informed subscale 56.9 (23.7) 58.5 (24.2) 0.6214
Support subscale 36.6 (19.7) 37.2 (18.4) 0.8422
Values Clarity subscale 48.6 (23.2) 45.1 (22.9) 0.2524
Effective Decision subscale 39.1 (19.5) 37.8 (16.5) 0.5880
Decisional Self-Efficacy Scale (DSES) (mean, SD) 85.9 (15.6) 85.6 (16.1) 0.8738
anumerical variables t-test; categorical variables: X2 or Fisher’s exact test
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controls did not have access to PDA; crossovers from
the control to intervention group were not possible.
We assessed level of missing data for our key con-
structs and outcomes. No variables had >30 % missing
thus we imputed missing data using a monotone data
Markov-Chain-Monte-Carlo (MCMC) method (SAS/
STAT procedure MIANALYZER) [48]. Analyses were
computed using SAS (SAS Institute, Inc, Cary, NC).
Data collection, quality and integrity
The survey software system (Qualtrics®) that was used to
enroll, screen, and implement surveys has a variety of fea-
tures to ensure data integrity. The survey questionnaires
could only be completed by the person to whom links
were sent, IP addresses were independently assessed to
verify no unauthorized access, and data were written dir-
ectly to the secure Qualtrics® database, which could not
reviewed or changed once submitted by subjects as
complete. All staff analyzing data were blinded to treat-
ment group assignment. Referring clinicians were blinded
to group assignment, unless they were incidentally un-
blinded by subjects during a clinical consultation subse-
quent to enrollment (e.g., subjects mentioning the PDA or
its contents during an office visit).
Power analyses
Our study was powered to measure the impact of the
PDA on the primary outcome of knowledge, using a 2-
tailed test. In a Cochrane systematic review of 42 studies
(10842 participants) measuring the impact of PDA vs
usual care on knowledge the effect size was 13.34 [11.17,
15.51] [26]. Our study with a sample size of 110 in each
of two arms was projected to have a 90 % chance to de-
tect a difference of 13.34 or greater in knowledge gained.
Results
We randomized 225 subjects into the study (Fig. 2), 114
to the PDA and 111 to usual care. All subjects were
followed for approximately 6 weeks after randomization
except for 20 who were lost to follow-up (PDA group, n =
15; usual care group, n = 5). Twenty seven (27) clinicians
enrolled at least 1 subject, with 15 enrolling more than
five subjects.
Baseline demographic and clinical characteristics are pre-
sented in Table 1. The mean age of all subjects was 52.3
[sd 12.7] years, the majority were female (54.7 %) and non-
Caucasian (55.5 %). Mean duration since T2DM diagnosis
was 6.6 [sd 5.7] years. Baseline demographics and comor-
bidities were similar across both groups, with two excep-
tions. Fewer subjects in the PDA versus UC group
reported having some college education (26.3 % vs 39.6 %,
respectively), and fewer had a history of a yeast or urinary
tract infection (UTI). Most (57.3 %) had not begun consid-
ering their choices for medications; most (71.1 %) preferred
an active role in health care decision-making, either shared
with their physician, or independently (Table 2).
Figure 3 compares the importance that participants
placed on different outcomes affected by treatment (‘sub-
ject values’). There were no differences between the study
groups so both groups were combined. The most import-
ant values were a medication’s ability to manage blood
sugar to a goal, followed closely by avoidance of side-
effects. Least important were the convenience of dosing.
Knowledge outcomes
Subjects in the PDA group gained substantially more
knowledge than those in the UC group at 6 week follow-
up (35.0 % versus 9.9 % improvement in scores, respect-
ively, p < 0.0001). (Table 3) This corresponds to subjects in
the PDA group correctly answering nine of 17 knowledge
questions regarding medication treatments. Knowledge
confidence also improved substantially more in the PDA
group versus UC (11.0 [sd 12.8] versus 1.6 [sd 8.9] respect-
ively (p < 0.0001). In both groups, knowledge confidence
score was correlated with knowledge, r = 0.476 (p < 0.001).
In multivariate analyses that adjusted for gender, educa-
tional level, race, stage of decision-making, importance of
cost in making medication decisions, comorbidities, and
other factors, PDA use (versus usual care) was associated
with a greater likelihood of knowledge score gains, 26.6
percentage points (p < 0.0001) and a 10.1 points (p <
0.0001) gain in knowledge confidence (Table 4).
Decisional self efficacy and decisional conflict outcomes
PDA users, as compared to UC, had substantially larger
likelihood of improvements in both decisional self-
efficacy (3.7 vs−3.9, respectively) and decisional conflict
(−22.2 vs−7.5, respectively) within 6 weeks of enroll-
ment, differences which were highly statistically signifi-
cant (p < .0001). The mean DCS score among PDA
users at final follow-up was well under 25 (23.6 [sd
14.3]). Significant improvements in each of the deci-
sional conflict scale sub-scores were observed (Table 3).
Multivariate analyses adjusting for educational, race,
stage of decision-making, importance of cost in making
medication decisions, previous yeast or urinary tract infec-
tions, and other factors found that PDA use was associ-
ated with a substantial likelihood of decline in decisional
conflict (−16.25 (p < 0.0001)) and improvement in deci-
sional self-efficacy ( 7.44 [p = 0.004]) (Table 4).
Among those assigned to the intervention group, 95
(83.3 %) responded to a brief email survey shortly after
viewing the PDA. 94 (98.9 %) reported the information was
“just right” and “well balanced” and 90 % that the informa-
tion was sufficient to understand each class of antihyper-
glycemic agent’s effectiveness and side effects. Twelve
(12.6 %) found the length of the material “too long”. Ten
clinicians who enrolled a minimum of ten subjects were
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Fig. 2 Subject Disposition
Table 2 Baseline decisional characteristics
PDA Usual Care p-valuea
n = 114 n = 111
Stage of Decision-making n (%) n (%)
Haven’t begun to think about the choices 37 (32.5) 31 (27.9) 0.4596
Haven’t begun to think about the choices, but am interested in doing so 30 (26.3) 31 (27.9) 0.7856
...are considering the options now 18 (15.8) 26 (23.4) 0.1489
...are close to selecting an option 3 (2.6) 1 (0.9) 0.6218
Have already made a decision, but am still willing to reconsider 15 (13.2) 14 (12.6) 0.9029
Have already made a decision and am unlikely to change my mind 11 (9.7) 8 (7.2) 0.5101
Control Preference
Doctor-oriented 34 (29.8) 31 (27.9) 0.7537
Shared 51 (44.7) 58 (52.3) 0.2594
Independent 29 (25.4) 22 (19.8) 0.3142
aX2 test or Fisher exact test
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asked to re-review the PDA at the end of the study and an-
swer (a) similar question. Of the nine who responded, six
(66.6 %) endorsed the statement that the PDA “could help
patients to fully understand the risks and benefits of
treatment options for T2DM” either “a great deal” or
“quite a bit”, with the remainder (33.3 %) responding
“at least somewhat”.
Discussion
Engaging patients and their families as active partici-
pants and collaborators in care is critical for achieving
patient centered health care in the U.S., improving the
patient experience of care, improving outcomes and re-
ducing the per capita costs of health care [49]. Among
people with diabetes, the Diabetes Attitudes, Wishes and
Needs (DAWN2) study recently indicated that engage-
ment and participation by people with diabetes is lack-
ing, but is a high priority for both patients and health
professionals [50, 51]. In addition, patient engagement is
particularly important in the management of high-risk
diabetes patients [52]. However, shared decision-making
that provides the amount and depth of information tar-
geted to what is important to patients in support of
meaningful patient-provider collaboration is time con-
suming and contributes to delays in the advancement
and intensfication of treatment [53, 54]. The develop-
ment and use of health information using technology
platforms, such as this PDA, is effective, acceptable to
patients, and has the potential to provide the knowledge
and confidence patients need to more fully participate in
shared decision-making and become true partners in
self-management and their future health. To support
communication and engagement in decision making, we
developed and tested the Diabetes Decision Aid for
T2DM. This decision aid is the first for T2DM widely
available in an electronic format that not only provides
targeted information on medication choices, but also
facilitates users’ understanding of personal values re-
lated to important aspects of the medication decision
through a values a clarification exercise, including each
option’s risks and benefits. Values clarification help pa-
tients understand and recognize if treatment decision
are consistent with the priorities identified in the exer-
cise. Helping patients make explicit value assumptions
may support decision-making processes with fuller un-
derstanding and buy in, which is integral to one’s self-
Fig. 3 Subject Values Scores At Baseline for Outcomes Related to Treatment
Table 3 Change in Scores between Baseline and Final Follow-up
PDA Usual Care p-valuea
n = 114 n = 111
(Mean Δ, SD) (Mean Δ, SD)
Knowledge (% correct) 35.0 % (22.3) 9.9 % (22.2) <.0001
Knowledge confidence 11.0 (12.8) 1.6 (8.9) <.0001
Decision Self-Efficacy scale 3.7 (16.7) −3.9 (19.2) 0.0018
Decisional Conflict Score (total)b −22.2 (20.6) −7.5 (16.6) <.0001
Uncertainty subscale −21.3 (27.3) −9.5 (23.5) 0.0006
Informed subscale −29.9 (26.5) −8.4 (27.4) <.0001
Values Clarity subscale −27.1 (24.4) −8.9 (22.1) <.0001
Support subscale −19.1 (20.7) −5.8 (17.1) <.0001
Effective Decision subscale −15.7 (22.1) −5.4 (18.6) <.0001
at-test
bLower is considered better
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Table 4 Adjusted analyses – primary and secondary outcomes. Generalized linear model regression model -primary and secondary outcomes
Percent Correct Response Δ Knowledge Confidence Δ Decisional Conflict Δ Decisional Self Efficacy Δ
Coefficient (SE) P value,5 % CI Coefficient (SE) P value, 95 % CI Coefficient (SE) P value, 95 % CI Coefficient (SE) P value, 95 % CI
PDA Group 26.60 (3.23) <.0001 (20.23, 32.96) 10.13 ( 1.54) <.0001 (7.10, 13.17) −16.25 (2.57) <.0001 (−1.33, −11. 18) 7.44 (2.56) 0.004 (2.39, 12.49)
Male 6.74 (3.26) 0.040 (0.31, 13.18) 1.27 (1.55) 0.414 (−1.79, 4.34) 1.78 (2.60) 0.494 (−3.34, 6.91) 0.67 (2.59) 0.796 (−4.43, 5.77)
Non-adherence with PDA −0.50 (6.77) 0.941 (−13.85, 12.85) −5.57 (3.23) 0.086 (−11.93, 0.79) 8.02 (5.39) 0.139 (−2.62, 18.65) −6.65 (5.37) 0.217 (−17.24, 3.94)
Education – Grade School* −4.34 (14.27) 0.762 (−32.48, 23.80) −6.92 (6.80) 0.310 (−20.33, 6.49) −28.07 (11.37) 0.014 (−50.49,−5.65) 20.28 (11.32) 0.075 (−2.04, 42.60)
Education – Some High School* −5.31 (8.07) 0.512 (−21.22, 10.61) −6.14 (3.85) 0.112 (−13.72, 1.44) 7.39 (6.43) 0.252 (−5.29, 20.06) −3.72 (6.40) 0.562 (−16.34, 8.90)
Education – High School Graduate* 1.55 (5.61) 0.782 (−9.51, 12.62) −5.88 (2.55) 0.002 (−13.78, 3.24) 3.81 (4.47) 0.396 (−5.01, 12.62) −2.90 (4.45) 0.516 (−11.68, 5.88)
Education – Some College* 4.98 (5.36) 0.354 (−5.58, 15.54) −7.31 (2.67) 0.022 (−10.92,−0.85) −1.56 (4.27) 0.716 (−9.97, 6.85) −6.05 (4.25) 0.156 (−14.42, 2.33)
Education – College Graduate* 2.67 (5.61) 0.635 (−8.40, 13.73) 3.78 (2.85) 0.007 (−12.58,−2.04) 2.11 (4.47) 0.638 (−6.71, 10.92) −5.57 (4.45) 0.212 (−14.35, 3.20)
Stage of Decision-making† - Have not
begun to think about choice
−2.03 (5.99) 0.735 (−13.83, 9.77) −7.31 (2.67) 0.186 (−1.84, 9.41) −12.86 (4.77) 0.008 (−22.26,−3.46) 3.90 (4.75) 0.413 (−5.46, 13.26)
Stage of Decision-making†- Have not
begun to think about choice,
but interested
1.36 (6.15) 0.825 (−10.76, 13.49) 6.71 (2.93) 0.023 (0.93, 12.49) −11.78 (4.90) 0.017 (−21.44,−2.12) 6.7 1 (4.88) 0.171 (−2.91, 16.33)
Stage of Decision-making†- Considering
options/close to selecting
1.05 (6.40) 0.870 (−11.57, 13.67) 5.75 (3.05) 0.061 (−0.27, 1 1.76) −14.64 (5.10) 0.005 (−24.7, −4.58) 2.34(5. 08) 0.645 (−7.67, 12.35)
Stage of Decision-making†-already
made decision, but willing to consider
0.54 (6.83) 0.938 (−12.94, 14.01) 5.68 (3.26) 0.083 (−0.74, 12.10) −7.37 (5.44) 0.177 (− 18.11, 3.36) 6.37 (5.42) 0.241 (−4.32, 17.06)
Previous yeast or UTI History −0.82 (4.62) 0.860 (−9.92, 8.28) 1.80 (2.20) 0.414 (−2.54, 6.14) −3.24 (3.68) 0.379 (−10.49, 4.01) −0.42 (3.66) 0.909 (−7.64, 6.80)
Values -finding lowest cost option −0.14 (0.64) 0.825 (−1.40, 1.12) −0.06 (0.30) 0.840 {−0.66, 0.54) −0.20 (0.51 ) 0.698 (−1.20, 0.81) 0.67 {0.51) 0.190 (−0.33, 1.67)
Race- Black/African American± −0.24 (3.81) 0.950 (−7.75, 7.27) −0.96 (1.82) 0.598 (−4.54, 2.62) −0.18 (3.04) 0.954 (−6.16, 5.81) −0.66 (3.02) 0.828 (−6.62, 5.30)
Race - Hispanic ± −3.35 (4.84) 0.489 (l2.89, 6.19) −1.86 (2.30) 0.422 (−6.40, 2.69) 2.78 (3.85) 0.471 (−4.81, 10.38) −6.27 (3.84) 0.104 (−13.84, 1.29)
Race - Other± −2.27 (4.95) 0.647 (−12.03, 7.48) 2.06 (2.36) 0.384 (−2.59, 6.70) 5.37 (3.94) 0.175 (−2.41, 13. 14) 1.23 (3.92) 0.755 (−6.51, 8.97)
Intercept 5.91 (8.67) 0.49 (11.18, 23.01) 2.75 (4.13) 0.507 (−5.40, 10.90) 3.10 (6.91) 0.654 (−10.52, 16.72) −8.56 (6.88) 0.215 (−22 12, 5.00)
*Reference condition: Education – Graduate School















confidence or belief in the ability to make decisions
(decision self-efficacy) [55, 56].
PDA use was associated with substantial and signifi-
cant improvements in knowledge about T2DM medica-
tion, decisional self-efficacy, and decisional conflict in a
large socio-demographically diverse sample. We discov-
ered several apparent contradictions. Even though all
subjects had been advised by their provider to consider
additional antihyperglycemic medication, more than half
of the subjects in both groups reported that they had
not begun to consider their treatment options. Most
(70 %) participants preferred an active role in decision-
making, yet few had adequate knowledge to make a
good decision. This suggests a substantial unmet need to
both activate patients to engage in decision-making and
to help them improve their knowledge about T2DM and
its treatment.
Knowledge
The gains in knowledge that we observed in our diverse
national sample (approximately 23 points on a normalized
scale) are consistent with findings from other PDAs
attempting to improve knowledge about diabetes antihy-
perglycemic medication options in different settings.
Branda et al. reported knowledge gains of 23.5 [95 % CI
9.7, 37.3] among a largely Caucasian sample of T2DM pa-
tients in rural Minnesota [35]. In this study, the patients
receiving the Diabetes Choice PDA achieved a final cor-
rect score of 57 % and the control group achieved a cor-
rect score of 33 %, similar to our findings of 55.5 and
32.5 % correct, respectively. Both studies demonstrated
that although gains in knowledge and knowledge confi-
dence were substantial in the PDA groups. The Statin
Choice Trial [28], conducted among patients with diabetes
exploring adding statins to their medication regimens,
found that their PDA improved knowledge of medication
risks and benefits by approximately 27 points in a highly
educated Caucasian population in Minnesota, adminis-
tered during a face-to-face consultation. The PANDAs
PDA [34] included predominantly well-educated Cauca-
sians in the UK and reported mixed results for knowledge
when two questions were asked to assess understanding
of medication effectiveness and risks. Our study provides
further evidence of a substantial gap in knowledge about
T2DM and its treatment in an educationally and racially/
ethnically diverse national sample. Our findings support
the need for better targeted patient education about
T2DM and antihyperglycemic treatments to help patients
prepare for shared decision-making [52].
Decsional self efficacy
Improvements in decisional self-efficacy were found in
the PDA group. This may have been due to the positive
relationship between self-reported efficacy expectations
and knowledge acquisition [15, 57]. An unexpected out-
come was a decrease in decisional self-efficacy in the UC
group. When people are confronted with a challenging
task, some may become less sure of their efficacy [58].
Baseline decisional self-efficacy was measured prior to
administering a detailed knowledge test and a question-
naire addressing the many factors that must be consid-
ered when selecting medication (e.g., minimizing the
risk of hypoglycemia, adverse events). Subjects may have
overestimated their self-efficacy at baseline [53], and UC
self-efficacy may have been negatively impacted upon
recognizing how little subjects actually knew about their
medication options and how many factors needed to be
considered. To our knowledge, this study is the first to
observe a decrease in self-efficacy in the control arm of
studies of treatment-focused patient decision aids. Of 115
studies in the current Cochrane systematic review, 8 mea-
sured the effect of decision aids on confidence when com-
paring decision aid use to usual care, 3 of which used
decisional self-efficacy as that measure of confidence.
None of these studies measured outcomes related to a de-
cision aid for diabetes and only one measured change in
DSES from baseline. Atterbern et al. [59] randomized sub-
jects to a video PDA vs written materials for information
regarding bariatric surgery. No decreases in self-efficacy
were observed in the control group receiving the pamph-
let, and no significant differences in DSES change from
baseline were observed in the treatment group versus the
control group.
Decisional conflict
The PDA significantly lowered overall decisional conflict
and each of its subscales. Mean DCS scores at final
follow-up were <25, the threshold below that equates to
making an effective decision [43]. Some of these findings
were unexpected because the PDA did not explicitly tar-
get some of the domains measured by the subscale, such
as feeling more supported in their decision-making.
Only six of 15 treatment-related PDAs in the most re-
cent Cochrane review reported significant findings for
this subscale [26]. These improvements in decisional
conflict subscales may reflect unique features of our
PDA, such as tailoring information according to the pa-
tients’ preferences (e.g., expected degree of glycemic
control, and durability of control; impact on weight; risk
of hypoglycemia; costs). This type of tailoring might
make patients feel more supported in their choice. The
PDA also includes interactive values clarification exer-
cises that help patients weigh relative the importance of
each of these values, which is different than the more
common static printed or videotaped PDA material.
These exercises may explain our positive impact on the
values clarity subscale.
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Limitations
Our study has several limitations. First, our blinding of re-
ferring clinicians prevented us from engaging providers in
shared decision-making training, which has been shown to
augment the effect of PDAs [60]. Thus our findings may
underestimate the impact of our PDA where provider
shared decision-making training is included. On the other
hand, subjects were not blinded to treatment assignment,
and this may have impacted results due to expectations
raised regarding PDA participation benefits. Also, because
viewing the PDA and assessments were conducted over
the internet, results may not be generalizable to a less-
internet experienced audience, or to an audience with so-
cioeconomic barriers to internet access. Our choice of a
comparator, usual care, is not an ideal comparison for PDA
assessments. An alternative may have been to randomize
control subjects to a time-matched subject information
page. This would help assure that differences between
groups was related to PDA content, and not the system of
support inherent and facilitated by the PDA delivery sys-
tem. Our sample size was relatively small, thus larger stud-
ies are warranted. Although we enrolled a diverse group of
subjects, we did not directly measure literacy or numeracy
but instead used educational level as a proxy.
Conclusions
This study provides insights into the impact of a novel
interactive PDA for subjects with T2DM for whom first
line treatment with metformin is no longer effective.
The PDA helps patients acquire essential knowledge to
make informed decisions according to their personal
values and preferences. It substantially and significantly
improved knowledge, decisional self-efficacy, and deci-
sional conflict among a diverse group of patients with
T2DM. We developed a Spanish translation of the PDA
for a Latino/Hispanic audience, but have not yet tested
it. It would be important to understand its impact in
Spanish-speaking populations. The PDA is currently
available and being deployed in a variety of US health
systems (www.diabetesdecisionaid.com. Future studies
should assess the impact of PDA on medication choice,
medication adherence, patient-provider communication,
glycemic control, other clinical outcomes, and costs.
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